Pediatrix director receives 7,196-share stock grant

Young Sylvia Jean reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

Young Sylvia Jean reported acquisition or exercise transactions in this Form 4 filing.

Pediatrix Medical Group director Sylvia Jean Young reported an equity award of common stock. She received 7,196 restricted shares of Pediatrix Medical Group, Inc. common stock on May 7, 2026, as a grant under the company’s Amended and Restated 2008 Incentive Compensation Plan in connection with her annual equity award.

The restricted shares were granted at no cash cost to her and will vest on May 7, 2027, subject to the plan’s terms. After this award, she now directly holds 47,814 shares of Pediatrix common stock, reflecting her ongoing equity-based compensation and alignment with shareholders.

Insider Trade Summary

Grant/Award: 7,196 shares

Grant/Award 1 txn

Insider Young Sylvia Jean

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	7,196	$0.00	$0.00

Holdings After Transaction: Common Stock — 47,814 shares (Direct)

Footnotes (1)

1. F1. Restricted shares granted pursuant to Issuer's Amended and Restated 2008 Incentive Compensation Plan, in connection with annual equity award. Shares will vest on May 7, 2027.

Key Figures

Restricted shares granted: 7,196 shares Grant price: $0.0000 per share Shares held after transaction: 47,814 shares +1 more

4 metrics

Restricted shares granted 7,196 shares Common Stock award on May 7, 2026

Grant price $0.0000 per share Equity award under 2008 Incentive Compensation Plan

Shares held after transaction 47,814 shares Total direct holdings following grant

Vesting date May 7, 2027 Restricted shares vesting schedule

Key Terms

Restricted shares, Amended and Restated 2008 Incentive Compensation Plan, annual equity award

3 terms

Restricted shares financial

"Restricted shares granted pursuant to Issuer's Amended and Restated 2008 Incentive Compensation Plan"

Restricted shares are company stock that cannot be sold or transferred immediately because they are subject to legal or contractual limits, such as a required holding period or performance conditions. They matter to investors because these locked-up shares can affect a company’s available stock for trading, future dilution, and insider incentives—imagine a gift that can’t be cashed until certain conditions are met, which changes when and how much supply can suddenly enter the market.

Amended and Restated 2008 Incentive Compensation Plan financial

"granted pursuant to Issuer's Amended and Restated 2008 Incentive Compensation Plan"

annual equity award financial

"Incentive Compensation Plan, in connection with annual equity award"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Pediatrix Medical Group (MD) report?

Pediatrix Medical Group reported a director equity grant. Director Sylvia Jean Young received 7,196 restricted shares of common stock as an annual equity award under the company’s 2008 Incentive Compensation Plan, with no cash paid per share.

How many Pediatrix (MD) shares did director Sylvia Jean Young receive?

Director Sylvia Jean Young received 7,196 restricted shares of Pediatrix common stock. These shares were granted as part of her annual equity award, increasing her direct holdings to 47,814 shares following the transaction reported in the Form 4 filing.

When do the newly granted Pediatrix (MD) restricted shares vest?

The newly granted restricted shares vest on May 7, 2027. Until that vesting date, the 7,196 restricted shares remain subject to the terms and conditions of Pediatrix Medical Group’s Amended and Restated 2008 Incentive Compensation Plan.

Was the Pediatrix (MD) director stock grant an open-market purchase?

The Pediatrix director stock grant was not an open-market purchase. It was a compensation-related award of 7,196 restricted shares granted at zero price per share under the company’s incentive compensation plan, rather than shares bought on the open market.

How many Pediatrix (MD) shares does Sylvia Jean Young hold after this award?

After this award, Sylvia Jean Young holds 47,814 Pediatrix common shares directly. This total includes the 7,196 restricted shares granted as part of her annual equity award, as reported in the Form 4 insider transaction.

What plan governed the Pediatrix (MD) restricted share grant?

The restricted share grant was made under Pediatrix Medical Group’s Amended and Restated 2008 Incentive Compensation Plan. The 7,196 restricted shares were issued in connection with Sylvia Jean Young’s annual equity award and are scheduled to vest on May 7, 2027.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/11/2026 - 05:41 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Young Sylvia Jean

(Last) (First) (Middle)

1301 CONCORD TERRACE

(Street)

SUNRISE FLORIDA 33323

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Pediatrix Medical Group, Inc. [ MD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/07/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/07/2026		A(1)		7,196	A	$0	47,814	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Restricted shares granted pursuant to Issuer's Amended and Restated 2008 Incentive Compensation Plan, in connection with annual equity award. Shares will vest on May 7, 2027.

Remarks:

See Exhibit 24.1 - Power of Attorney

	Mary Ann E. Moore, Attorney-in-Fact	05/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)